Press Release

« Back

Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that it will participate in two upcoming investor conferences:

  • 29th Annual Piper Jaffray Healthcare Conference 
    Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer of Ovid, will participate in a fireside chat on Wednesday, November 29, 2017 at 9:30 a.m. ET. The conference will be held at the Lotte New York Palace Hotel in New York, NY.

  • Evercore ISI 2017 BioPharma Catalyst/Deep Dive Conference 
    Yaron Werber, MD, chief business and financial officer of Ovid, will participate in a fireside chat on Thursday, November 30, 2017 at 12:50 p.m. ET. The conference will be held at the at the Boston Harbor Hotel in Boston, MA.

Live audio webcasts of the fireside chat discussions can be accessed through the Events & Presentations section of the company's website at Archived replays of the webcasts will be available on the company's website for two weeks following each live discussion.

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies and has initiated a Phase 1b/2a trial of OV935.

For more information on Ovid, please visit

Ovid Contacts:
Burns McClellan
Steve Klass, 212-213-0006

Pure Communications, Inc.
Katie Engleman, 910-509-3977

Ovid Therapeutics Inc.